The REALYSA study aims to improve knowledge about lymphomas and the lives of patients with lymphomas. Thanks to the large number of patients who participate, it allows sub-studies to be conducted simultaneously on specific research questions. One of its sub-studies, called CLARITY, is in patients with large B-cell lymphoma.
Why is this study being implemented?
Large B-cell lymphomas are the most common type of non-Hodgkin lymphoma. They represent about 40% of the patients included in the REALYSA cohort. One of the goals of REALYSA is to better understand the demographic and clinical characteristics of adult lymphoma patients in France, as well as to describe the treatments they receive and how they respond. In this context, the CLARITY study focuses more specifically on patients with large B-cell lymphoma. It will make it possible to build and analyze a cohort of about 2000 patients with this type of lymphoma.
What are the objectives of the study?
The study aims to describe patients with large B-cell lymphoma treated in the 1st line. The aim is to analyse their demographic data (age in particular), their state of health and the evolution of this over time.
The study also aims to find out what treatments these patients received and with what effectiveness, according to the age or biological characteristics of the lymphoma.
This so-called “real-life” data (as opposed to clinical trials) will be useful to better understand how patients are being cared for and what improvements should be considered.
How will the study be carried out?
The study will be based on the analysis of data from the medical records of patients participating in REALYSA. These analyses will be carried out by members of LYSARC.
This study is carried out in collaboration with Dr. Stéphanie Guidez (University Hospital of Poitiers) and the Astra-Zeneca laboratory, a partner of REALYSA. The laboratory will only receive descriptive reports, without individual data. No link can be made between the data contained in the reports and the patients participating in REALYSA.
The results sent to Astra-Zeneca will be used to compile regulatory dossiers for the French health authorities, in order to provide information on the current care of patients.
The study will begin in February 2026.
TO THE ATTENTION OF PATIENTS PARTICIPATING IN REALYSA
What does this project implies for you?
This study only concerns patients participating in REALYSA who have large B-cell lymphoma.
If you are in this situation and you agree to have your data used for this study, it has no direct implications for you.
In particular, you will not have to answer any additional questionnaire compared to what is already planned as part of your participation in REALYSA.
What should you do about this study?
There are two options:
- You are not opposed to the use of your data in the context of this study:
- In this case, you don’t have to do anything.
- You wish to object to the use of your data in the context of this study:
- In this case, you must inform the doctor who offered you to participate in the REALYSA study or DESCAR-T. You can also notify your decision by writing an email to the following address: dpo@lysarc.org .
You will find detailed information on your rights to object to the use of your data on page 12 of the information notice that was given to you when you agreed to participate in REALYSA.